Table 8 Cost-utility analysis of benralizumab at 1 year of treatment
From: Real-life cost-effectiveness of benralizumab in patients with severe asthma
Period | Mean utility (SD) | Mean total cost (Euros) | Increase | Incremental cost utility ratio | |
|---|---|---|---|---|---|
Utility | Costs | ||||
Previous 12 months (baseline) | 0.729 (0.071) | 11,544 (9137) | 0.138 | 2499 | 18,177 |
At 12 months on benralizumab | 0.867 (0.039) | 14,043 (3822) | |||